Drug distribution becomes weapon to block competition

WASHINGTON -- The same strategy that Martin Shkreli used to get away with a 5,000-per cent price increase on an old drug is used by many other drugmakers to maintain sky-high prices on billions of dollars' worth of medications.

See Full Article

Before the price hike that made him infamous, the former CEO of Turing Pharmaceuticals had to ensure that no competitor would be able to launch a cheaper version of Daraprim, the 60-year-old anti-infection pill that is no longer under patent.

Shkreli had the perfect weapon: a tightly-controlled distribution system which would make it virtually impossible for a competitor to obtain enough Daraprim to develop their own version.

Shkreli, who resigned in December, did not invent the closed distribution technique. And his former company, Turing, notes that Daraprim was already distributed under such a system when it acquired the drug.

Many larger drugmakers have also turned drug distribution into a powerful tool against competition. The strategy takes advantage of a simple fact: If generic drugmakers can't get their hands on the original product, they cannot perform the tests needed to develop a generic version. Typically generic drugmakers purchase drugs in bulk from third-party suppliers. But when the original drugmaker controls the drug's distribution, they can simply refuse to sell.

The effect on patients is higher prices for drugs that would otherwise be available as low-cost generics. Doctors say these tactics "continue to stand in the way of patients' access."

"The most effective way to improve access and lower prices is to ensure that generic drugs get to market as quickly as possible," says Dr. Ameet Sarpatwari, of Harvard Medical School, who has studied the issue.

At least 40 drugs worth an estimated $5.4 billion are sheltered from competition by distribution hurdles, according to a study commissioned by the Generic Pharmaceutical Association, an industry trade group.

The Food and Drug Administration is aware of the misuse of distribution programs. The agency said in a statement it has received 100 letters from companies that say they have been blocked from obtaining drugs for testing purposes. The agency's own regulations prohibit drugmakers from using certain types of distribution plans to block generic access, but the agency does not penalize companies for the practice.

The trend began in 2007, when the FDA began requiring risk-management plans for certain drugs. The plans often feature various restrictions to make sure drugs are used safely, including limits on who can distribute them. But drugmakers realized these measures could also be used to keep their drugs away from competitors. And even drugs that didn't require risk-management could utilize the strategy.

Daraprim is an example of a drug that has no major safety risks and was previously available through various wholesalers and distributors. But last June - three months before its sale to Turing - Daraprim was moved into a closed distribution program, allowing the manufacturer to refuse sales to competitors.

The effect for patients was jarring. The drug - which treats an infection mainly found in people with HIV and cancer - had previously been available through local pharmacies. Now it is distributed through a specialty division of Walgreen's, which sells the drug at Turing's list price of $750 per pill. In the months after the price hike, some patients faced co-pays as high as $16,000 when trying to fill a prescription.

"Mr. Shkreli set up a very complicated system to ensure profits and patients have really suffered," says Sean Dickson, of the National Alliance of State and Territorial AIDS Directors.

Turing says it has improved access to Daraprim, including making it available through a patient assistance program for those that can't afford it.

Drugmakers argue that closed distribution simply protects their interests, making sure drugs are shipped and handled appropriately.

But generic drugmakers say the tactics threaten their business model.

"It undermines the whole generic drug approval process," said Steve Giuli, an executive with generics firm Apotex Corp.

Apotex has repeatedly tried to purchase two specialty cancer drugs sold by drugmaker Celgene. Together the drugs, Thalomid and Revlimid, account for $5.2 billion in sales, more than two-thirds of Celgene's revenue for 2014. That's the despite the fact that Thalomid is a 1950s-era drug whose key ingredient is no longer under patent. Because the drug can cause severe birth defects, it is subject to a rigorous distribution program controlled by Celgene.

"They will never freely sell you the product, even if you negotiate with them for weeks, months, and perhaps years to satisfy all of their onerous concerns," says Omar Jabri, another Apotex executive.

A Celgene spokesman did not return calls and emails seeking comment on the risk-management program.

In one case, New Jersey-based Celgene went on the offensive, suing Barr Laboratories for attempting to introduce a generic version of Thalomid. Celgene said Barr's effort would infringe on its intellectual property, since it had patented Thalomid's risk-management plan.

When generic drugmaker Lannett sued Celgene in 2012, alleging that the company's tactics illegally blocked competition, the companies reached an out-of-court settlement. Details of the agreement were not disclosed but Thalomid remains unavailable as a generic.

Meanwhile, the FDA has remained on the sidelines.

"The FDA is hesitant to make a call on whether a manufacture is actually intending to delay generic competition," explains pharmaceutical attorney Kurt Karst.

With no apparent solution from the courts or the FDA, generic drugmakers and their allies are seeking a fix from Congress.

A bill introduced in the House would direct the FDA to impose stiff fines on drugmakers that refuse to sell their products to generic drugmakers.

Introduced last summer, the legislation has made little headway on Capitol Hill, but Dr. Sarpatwari hopes recent concerns about drug prices will attract more attention to the proposal.

"You're getting Congress to amend the system to require that drug samples be shared under the penalty of actual sanctions," he says. "That's ultimately where we need to get to."



Advertisements

Latest Economic News

  • Employment scam tops BBB's list of top scams for 2016

    Economic CBC News
    Canadians lost a reported $90 million to scams last year, according the Better Business Bureau's list of the top ten scams of 2016 The list was compiled with information gathered from the Bureau's scam tracker website, the Canadian Anti-Fraud Centre and concerns from community partners. Source
  • Air Miles sends belated apology to collectors after learning 'humbling lessons' in 2016

    Economic CBC News
    Air Miles wants to make amends with its members for a rough 2016, so it's emailing them an apology of sorts starting Wednesday morning. The year was "challenging" and "we learned very difficult, public and humbling lessons," Blair Cameron, head of Air Miles, says in the letter. Source
  • Hershey expects to cut 15 per cent of global workforce

    Economic CTV News
    HERSHEY, Pa. -- Hershey expects to cut its global workforce by about 15 per cent, with the reductions coming mostly from hourly employees outside the United States. The Pennsylvania chocolate maker also trimmed its forecast for long-term sales growth to between 2 per cent and 4 per cent, down from the previous 3 per cent to 5 per cent. Source
  • Women's retailer BCBG Max Azria seeks creditor protection, will close stores in Canada

    Economic CBC News
    Women's upscale fashion retail chain BCBG Max Azria is seeking protection from creditors in the North America, and plans to restructure, including closing all its standalone stores in Canada. The chain, founded in Los Angeles in 1989, has grown to 550 stores worldwide. Source
  • Uber CEO caught on video arguing about fares

    Economic CTV News
    LONDON -- Uber's CEO says he needs leadership help after a video has emerged of him arguing with a driver about fares. In a video obtained by Bloomberg News, Travis Kalanick is seen discussing Uber's business model with the driver. Source
  • Uber CEO, after outburst caught on video: 'I need leadership help'

    Economic CTV News
    Uber's CEO says he needs leadership help after a video has emerged of him arguing heatedly with a driver about fares. In the latest embarrassment to beset the ride-hailing company, CEO Travis Kalanick is seen discussing Uber's business model with the driver. Source
  • Ont. man denied $10,000 jackpot over casino 'self-exclusion' rule

    Economic CTV News
    An Ontario man was shocked when he recently won more than $10,000 at a casino, only to be told he wasn’t eligible to collect his winnings. John Marando, 82, recently thought he had met a run of great luck, when he won a jackpot while playing a slot machine at the Mohawk racetrack outside of Milton, Ont. Source
  • New York City's Waldorf Astoria closing for major makeover

    Economic CTV News
    NEW YORK -- The word "grand" matched few hotels in the world better than New York City's Waldorf Astoria, but this bastion of gilded splendor is now closing for two to three years for a transformative makeover. Source
  • Cape Breton's underground coal mining resumes after 15 years

    Economic CTV News
    DONKIN, N.S. - Underground coal mining has restarted in Cape Breton, more than 15 years after the fossil fuel was last cut from a rock face beneath the island. A news release from a minority stakeholder in the operation says 64 employees and contractors have been working at the Donkin project site since Monday night. Source
  • With no rate change expected, analysts to scrutinize BoC's words

    Economic CTV News
    OTTAWA -- With the Bank of Canada widely expected to leave its benchmark interest rate untouched Wednesday, analysts will focus on the tone of an announcement that arrives amid significant uncertainty about U.S. economic proposals. Source